Avidity Biosciences Inc Forecast, price target & analysts
Avidity Biosciences Inc Target price 2026 - Analyst rating & recommendation
Avidity Biosciences Inc Classifications & Recommendation
Avidity Biosciences Inc Price Target
| Target Price | $25.50 |
| Price | $8.42 |
| Potential |
202.85%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Avidity Biosciences Inc 2027 .
The average Avidity Biosciences Inc target price is $25.50.
This is
202.85%
register free of charge
$26.25
211.76%
register free of charge
$25.25
199.88%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Avidity Biosciences Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2027 of
202.85%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 18.62 | 34.70 |
| 70.83% | 86.37% | |
| EBITDA Margin | -264.82% | -2,174.52% |
| 121.19% | 721.12% | |
| Net Margin | -265.84% | -227.82% |
| 15.35% | 14.30% |
5 Analysts have issued a sales forecast Avidity Biosciences Inc 2026 . The average Avidity Biosciences Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2026. The average Avidity Biosciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Avidity Biosciences Inc Analysts have issued a net profit forecast 2026. The average Avidity Biosciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.89 | -4.62 |
| 96.60% | 59.86% | |
| P/E | negative | |
| EV/Sales | negative |
5 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Avidity Biosciences Inc...
Current Avidity Biosciences Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jun 18 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | May 15 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 11 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jun 18 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
May 15 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 11 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Oct 29 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
